Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review

@article{Ldaru2016CandidatePB,
  title={Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review},
  author={Anca Lădaru and P. Bălănescu and M. Stan and Ioana Codreanu and I. Anca},
  journal={Biomarkers},
  year={2016},
  volume={21},
  pages={102 - 114}
}
Abstract Context: Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver which is accompanied by a series of metabolic deregulations. There are sustained research efforts focusing upon biomarker discovery for NAFLD diagnosis and its prognosis in order investigate and follow-up patients as minimally invasive as possible. Objective: The objective of this study is to critically review proteomic studies that used mass spectrometry techniques and summarize… Expand
A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains
TLDR
A multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and proteomic variables is developed using data from 576 adults with extreme obesity who underwent bariatric surgery and intra-operative liver biopsy to indicate that multi-domain modeling has better predictive power than comprehensive analysis of variables from a single domain. Expand
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
TLDR
Currently available clinical prediction rules and blood-based biomarkers for identifying NASH and advanced fibrosis in patients with NAFLD are described, discussing their advantages and disadvantages, as well as their potential clinical utility for predicting dynamic changes over time and identifying patients at increased risk of adverse outcomes. Expand
Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study
TLDR
The plasma protein profile is significantly altered in nonalcoholic liver disease in children and may prove to be a valuable source of biomarkers to evaluate the extent of liver disease. Expand
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions
TLDR
A liver biopsy is required for a definitive NAFLD/NASH diagnosis, particularly to exclude other treatable conditions or when advanced liver disease is expected on clinical and laboratory grounds and preferably prior to any controlled trial of pharmacological/surgical treatments. Expand
NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?
TLDR
There is a great need for developing inexpensive, easily accessible, highly sensitive and specific biomarkers that permit not only the identification of patients at high risk of adverse outcomes, but also the monitoring of disease progression and response after therapeutic interventions. Expand
Stratified medicine : an exploration of the utility of non-invasive serum markers for the management of chronic liver diseases
TLDR
This work reviews the literature regarding the non-invasive detection of inflammation and fibrosis in CLD and explores the ability of candidate markers to detect non-alcoholic steatohepatitis prior to the development of advanced fibrosis prior to a derivation and validation cohort. Expand
Signaling in Simple Steatosis and Non-alcoholic Steatohepatitis Cirrhosis: TGF-β1, YAP/TAZ, and Hedgehog Pathway Activity
TLDR
The present review discusses the main changes in the expression of TGF-β, HH, and YAP/ TAZ pathway components in SS and NASH cirrhosis to provide a better understanding of the mechanisms that underlie the pathophysiology of NAFLD. Expand
Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease
TLDR
Current strategies for treating NAFLD and NASH based on multi-ingredient-based supplements or the Mediterranean diet, a dietary pattern rich in bioactive compounds, are reviewed. Expand
Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease
TLDR
The pilot data from this study suggest that changes in the HDL proteome may impact the functionality of HDL particles in NAFLD and NASH patients, and may alter cardio-protective properties of HDL, potentially contributing to the increased cardiovascular disease risk in affected individuals. Expand
Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease
TLDR
A possible mechanism by which the protein 17β-hydroxysteroid dehydrogenase 13 (17β-HSD13) may promote the development of NAFLD is discussed. Expand
...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease.
TLDR
The study showed that serum hemoglobin may have significant predictive value for NAFLD and suggested a protein peak to be hemoglobin subunit alpha. Expand
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease
TLDR
This novel proteomic strategy has identified a number of candidate biomarkers which may have benefit in the surveillance and diagnosis of individuals with chronic liver disease and/or HCC. Expand
Biomarkers in nonalcoholic fatty liver disease.
TLDR
The present review attempts to provide a comprehensive analysis of the emerging risk biomarkers of NAFLD and NASH, and to use the clinical significance and analytical considerations of each biomarker pointing out sentinel features of disease progression. Expand
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease
TLDR
Analysis of hepatic gene expression and serum protein content in patients with different subtypes of NAFLD suggests differential expression of several genes and protein peaks in patients within and across the forms ofNAFLD. Expand
Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry
TLDR
It is concluded that proteomic analyses of serum samples from NAFLD patients by MALDI TOF-MS do not seem to have a major clinical value for diagnosing NASH, however, the identification of 15 peaks in this study may help to further elucidate the pathophysiology of NASH and merits further investigation. Expand
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
TLDR
In patients with non-alcoholic fatty liver disease, NashTest, a simple and non-invasive biomarker reliably predicts the presence or absence of NASH. Expand
Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease
  • Wen Su, Y. Wang, +15 authors Y. Guan
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences
  • 2014
TLDR
The aim of this study was to determine the function of 17β-hydroxysteroid dehydrogenase-13 (17β-HSD13), one of the authors' newly identified LD-associated proteins in human subjects with normal liver histology and simple steatosis, in NAFLD development. Expand
Serum Complement C3f and Fibrinopeptide A Are Potential Novel Diagnostic Biomarkers for Non-Alcoholic Fatty Liver Disease: A Study in Qingdao Twins
TLDR
Two peptides derived from complement C3f and fibrinopeptide A had the highest ROC values indistinguishing NAFLD cases from their normal controls, and may be potential diagnostic markers or therapeutic targets forNAFLD. Expand
Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery
TLDR
The differential proteomic method demonstrated changes in serum protein profiles in obese patients according to severity of liver lesions, suggesting free haemoglobin subunits may serve as a serum biomarker of the severity of hepatitis B and C damages. Expand
Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.
TLDR
The gut microbiome in pediatric NAFLD is distinct from lean healthy children with more alcohol production and pathways allocated to energy metabolism over carbohydrate and amino acid metabolism, which would contribute to development of disease. Expand
...
1
2
3
4
5
...